The role of enkephalin and the opioid receptors in modulating GABA release within the rat globus pallidus (GP) was investigated using whole-cell patch recordings made from visually identified neurons. Two major GP neuronal subtypes were classified on the basis of intrinsic membrane properties, action potential characteristics, the presence of the anomalous inward rectifier (I h ), and anode break depolarizations.
and increased enkephalin immunoreactivity in the GPe (Lavoie et al., 1991) in animal models of parkinsonism. In keeping with the proposal that the GABA striatopallidal pathway is overactive after dopamine depletion, injection of GABA A receptor antagonists directly into the GP has been shown to increase locomotor score in parkinsonian animals (Maneuf et al., 1994) . Furthermore, direct injection of GABA A antagonists and and ␦ opioid receptor agonists into the ventral pallidum (the limbic homolog of the GP) of normal animals also promotes locomotor activity (Austin and Kalivas, 1990; Napier, 1992) . The effects of opioid receptor agonists have been attributed to the presynaptic inhibition of GABA release from striatopallidal terminals (Dewar et al., 1987; Maneuf et al., 1994) . Indeed, anatomical studies have provided evidence that opioid receptors are located on striatopallidal presynaptic terminals (Abou Khalil et al., 1984) . However, more recently, ligand binding, mRNA, and immunohistochemical studies have indicated the presence of both presynaptic and postsynaptic and ␦ opioid receptors within the GP (Delfs et al., 1994; Mansour et al., 1994 Mansour et al., , 1995 Bausch et al., 1995; Peckys and Landwehrmeyer, 1999) .
Two major types of GP neuron have been determined by in vivo and in vitro electrophysiological, morphological, and neurochemical experiments (DeLong, 1971; Hontanilla et al., 1994; Kita and Kitai, 1994; Llinás, 1994, 1997) . These neurons appear to display widespread intrinsic axon collaterals (Kita and Kitai, 1994; Nambu and Llinás, 1997) . Therefore, the presence of presynaptic opioid receptors within the GP may reflect receptor expression on collateral terminals, as well as striatopallidal terminals.
The aim of this study was therefore to determine (1) the presence and f unction of and ␦ opioid receptors on pallidal and striatal terminals, (2) the presence of f unctional postsynaptic and ␦ opioid receptors, and (3) whether there is a correlation between GP neuronal heterogeneity and differential opioid receptor activity.
MATERIALS AND METHODS
Whole-cell patch-clamp recordings were made from single GP neurons within 300-m-thick slices obtained from 80 -120 gm male Wistar rats. Animals were first anesthetized with fluorothane and killed by cervical dislocation. The brain was quickly removed and placed in ice-cold artificial C SF (aC SF) containing (in mM): choline chloride 126, KC l 2.5, NaH 2 PO 4 1.2, MgC l 2 1.3, MgSO 4 8, and glucose 10, buffered to pH 7.4 with NaHC O 3 26. Slices were cut in either coronal or parasagittal plane using a DTK-1000 Microslicer (Dosaka, Japan). Slices were then transferred to a holding chamber or recording chamber at 32-34°C and perf used continuously at 2-3 ml /min with aC SF containing (in mM): NaC l 126, KC l 2.5, NaH 2 PO 4 1.2, MgC l 2 1.3, C aC l 2 2.4, and glucose 10, buffered to pH 7.4 with NaHC O 3 26, saturated with 95% O 2 -5% C O 2 .
Whole-cell recordings from GP neurons were made using borosilicate glass pipettes of 3-6 M⍀ resistance containing (in mM): K-gluconate 125, NaC l 10, C aC l 2 1, MgC l 2 2, BAP TA 10, H EPES 10, GTP 0.3, Mg-ATP 2, and biocytin 5, adjusted to pH 7.25 with KOH. Individual neurons were visualized (40ϫ water immersion objective) using a differential interference contrast infrared microscopy (BX 501; Olympus Optical, Tokyo, Japan) with CCD camera (K P-M1; Hitachi, Tokyo, Japan) and contrast enhancement system (ADV-2; Brian Reece Scientific, Berkshire, UK). Recording pipettes were advanced while under positive pressure toward individual cells in the slice. On contact, tight seals, in the order of 10 -20 G⍀, were made by applying negative pressure. The membrane patch was then ruptured by suction, and membrane current and potential was monitored using an Axopatch 200B patch-clamp amplifier (Axon Instruments, Foster C ity, CA). Whole-cell access resistances were in the range of 7-20 M⍀ before electrical compensation by 65-80%. Access resistances, after electrical compensation, were initially determined in current-clamp mode and continuously monitored in voltage clamp by measuring the size of the capacitance transient in response to a 10 mV hyperpolarizing step (Stuart et al., 1993) . The access resistance was checked intermittently in current clamp, and experiments were abandoned if changes Ͼ20% were encountered. All current-clamp recordings were made in Axopatch 200B fast mode, and membrane potentials were corrected with respect to the null potential measured at the end of recording. No corrections have been made for the liquid junction potentials, estimated to be ϩ8 mV.
Synaptic events were evoked by focal bipolar single shock stimulation (0.5 msec, 0.1-3 mA) at 15 sec intervals using a constant current stimulation unit (DS2A; Digitimer, Hertfordshire, UK). Voltage steps were generated using pCL AM P software version 6.03 (Axon Instruments), and the resulting membrane currents and those resulting from synaptic activation were filtered at 2 kHz and stored on disk and digital analog tape recorder for subsequent analysis and display on a chart recorder (Gould Easygraph; Gould Instruments, Hainault, UK). To record mI PSC s, the K-gluconate in the recording pipette was replaced with KC l. In doing this, the theoretical chloride reversal potential moved from Ϫ61 to ϩ1 mV. mI PSC s were then recorded in tetrodotoxin (TTX) (1 M) at a potential of Ϫ80 mV. Data were collected over 2 min periods, acquired using F ETCH EX (Axon Instruments), and analyzed using Minianalysis software (Jaejin Software, Leonia, NJ).
Drugs were applied to the superf usate by exchanging the aC SF for one differing only by the addition of a known concentration of drug, with the exchange beginning after a dead time of ϳ20 sec. Drugs used were as follows: 6-cyano-7-nitroquinoxaline-2,3-dione (C NQX), All numerical data are expressed as mean and SE unless otherwise stated. Differences in I PSC data were analyzed for statistical significance using the paired Student's t test, and significant differences in the cumulative frequency and amplitude of spontaneous I PSC s (sI PSC s) and mI PSC s were analyzed using the Kolmogorov-Smirnov two-sample test (Jaejin Software).
RESULTS

Characterization of globus pallidus neurons
GP neurons were characterized by their electrophysiological properties and classified into two major groups. These two classes of neuron showed similar but not identical properties to the type I and II neurons described previously by Nambu and Llinás (1994) . Type I neurons were spontaneously active, firing irregular action potentials at 13 Ϯ 3.1 Hz (n ϭ 19) at a resting membrane potential of Ϫ52.4 Ϯ 7.8 mV (measured at I ϭ 0). The input resistance of these cells was 349 Ϯ 35.9 M⍀ (n ϭ 19), and action potential duration (taken as the time between the point of initiation of the maximum rate of depolarization and the equipotential point during spike repolarization) was 0.82 Ϯ 0.1 msec (n ϭ 19), followed by a short-lasting afterhyperpolarization (AHP) of amplitude 29.2 Ϯ 2 mV (n ϭ 19) (Fig. 1 A) .
Type II neurons were identified by the presence of the timeand voltage-dependent inward rectification of membrane potential evoked by hyperpolarizing steps of 300 msec duration and anodal break rebound depolarizations. These rebound depolarizations were often accompanied by action potential firing ( Fig.  1 B) . Type II neurons were either quiescent (22 of 38 cells) or fired regular spontaneous action potentials at a rate of 7.5 Ϯ 1.6 Hz (16 of 38) at a resting membrane potential of Ϫ53.4 Ϯ 2.5 mV. The input resistance of these cells was 646.1 Ϯ 41.8 M⍀ (n ϭ 38; significantly different from type I cells, p Ͻ 0.01), and the action potential duration was 1.1 Ϯ 0.1 msec (n ϭ 38; significantly different from type I cells, p Ͻ 0.01), followed by a prolonged AHP of amplitude 29.3 Ϯ 6.6 mV (n ϭ 38).
Evoked GABA A receptor IPSCs
At a holding potential of Ϫ50 mV, single shock electrical stimulation evoked a fast inward synaptic current, followed by a slower outward current. These currents appeared to be independent of slice orientation and stimulation location. The inward current was blocked by the glutamate antagonists CNQX (10 M) and DL-AP-5 (100 M) (Fig. 2 A) , whereas the slower outward current was blocked by bicuculline (10 M; n ϭ 4) ( Fig. 2 B) or picrotoxin (50 M; n ϭ 2) (data not shown). The outward current reversed polarity at approximately Ϫ70 mV (Fig. 2C) , close to the theoretical chloride equilibrium potential (E C l of Ϫ61 mV) and was therefore considered to be a GABA A receptor-mediated IPSC.
Opioid receptors on striatopallidal terminals
The opioid receptor modulation of GABA release from striatopallidal terminals was studied by stimulation within the striatum (in parasagittal slices) in the presence of CNQX (10 M) and DL-AP-5 (100 M). Obtaining robust synaptic responses using this orientation of slice and stimulation location proved technically difficult, possibly because of the topographic nature of striatopallidal connections (Wilson and Phelan, 1982) . However, application of the opioid receptor agonist DAMGO (1 M) reduced the IPSCs by 53 Ϯ 6% (n ϭ 7) (Fig. 3A) , whereas the ␦ opioid receptor agonist DPDPE was without effect (n ϭ 5) (Fig. 3B ). In each of these five cells, application of DAMGO (1 M) significantly reduced the evoked IPSC. The action of DAMGO appeared to be independent of cell phenotype, inhibiting IPSCs in three type I and four type II cells.
A paired-pulse protocol was used to show opioid receptor modulation of the striatal evoked IPSCs was presynaptic (Davies et al., 1990; Travagli and Williams, 1996) . I PSC s were evoked by single shock electrical stimulation of equal strength and duration at an interval of 30 msec. Application of DAMGO (1 M) reduced the amplitude of the conditioning (first) I PSC and test (second) I PSC but significantly increased the paired-pulse facilitation (21 Ϯ 10.7%; p Ͻ 0.05; n ϭ 4) (Fig. 3C ). This effect was totally abolished by preincubation (20 min) with the opioid receptor antagonist C TOP (1 M; n ϭ 3) (Fig. 3C ).
Met-enkephalin reduces the IPSCs evoked by stimulation within the GP via a presynaptic mechanism
Using coronal slices, electrical stimulation within the GP, 300 -900 m away from the recording site, evoked I PSC s that were reduced reversibly by bath application of met-enkephalin (30 M; 53.4 Ϯ 5.1%; n ϭ 11) (Fig. 4 A) . To determine the locus of such modulation, the action of met-enkephalin on the paired-pulse ratio and the frequency and amplitude of action potential independent mI PSC s was studied.
Met-enkephalin (10 -30 M) reduced the amplitude of the conditioning (first) and test (second) I PSC but increased the paired-pulse ratio (20.2 Ϯ 10.8%; p Ͻ 0.05; n ϭ 5) (Fig. 4 B) .
mIPSC s were recorded in chloride loaded cells at a holding potential of Ϫ80 mV in the presence of TTX (1 M), CNQX (10 M), and DL-AP-5 (100 M) (Fig. 4C ). IPSCs were considered "minis" after abolition by TTX (1 M) of electrically evoked synaptic currents and action potentials during depolarizing current steps. Bath application of met-enkephalin (30 M) significantly reduced the frequency of mIPSCs in five of seven cells ( p Ͻ 0.05), whereas the amplitude of mIPSCs was unaffected by met-enkephalin in six of seven cells (Fig. 4C) . These results suggest that met-enkephalin acts via presynaptic opioid receptors leading to a reduction of GABA release within the GP. Consistent with this interpretation, changes in holding current after met-enkephalin application were rarely observed. Only 4 of 19 cells exhibited a detectable outward current, which was 27.5 Ϯ 11.1 pA in amplitude (data from three type I and one type II neurons).
and ␦ opioid receptor agonists reduce IPSCs evoked by stimulation in the GP and mIPSCs
The ␦ opioid receptor agonist DPDPE (1 M) reduced the amplitude of the IPSC evoked by stimulation in the GP (in coronal slices) by 49.9 Ϯ 6.7% (n ϭ 8). The depression of the evoked IPSC by the opioid receptor agonist DAMGO (1 M) was more variable, ranging from 0 to 60% (mean, 29 Ϯ 9.8%; n ϭ 6) (Fig.  5) . The presynaptic action of both agonists was confirmed by analysis of mI PSC s. Bath application of DPDPE (1 M) significantly reduced the frequency of mI PSC s ( p Ͻ 0.05) in three of four cells (one type I and two type II neurons), whereas the amplitude of mI PSC s was not significantly reduced in three of four cells (Fig. 5B) . Application of DAMGO (1 M) significantly reduced the frequency of mI PSC s ( p Ͻ 0.05) in five of seven cells (two I and three II type cells), although the amplitude of events was not significantly reduced in six of seven cells (Fig. 5B) . These results confirm the presence of both presynaptic and ␦ receptors on terminals of both type I and II GP neurons, regulating GABA release within the GP.
Spontaneous IPSCs are reduced by but not ␦ opioid receptor agonists
In the presence of C NQX (10 M) and DL-AP-5 (100 M), 78% of GP neurons displayed outward sI PSC s (in nonchloride loaded electrodes). These currents reversed around E C l and were abolished by TTX (1 M; n ϭ 3) (Fig. 6 A) and picrotoxin (50 M; n ϭ 4; data not shown), suggesting action potential-dependent activity of GABA-releasing neurons within the preparation.
Met-enkephalin (30 M) caused a significant reversible depression in frequency of sIPSCs in 10 of 11 cells (five I type, five II type cells; p Ͻ 0.05), an effect that was mimicked by DAMGO (1 M; 9 of 11 cells; five I type and four II type neurons). However, DPDPE 1 M had no effect on the frequency of sIPSCs in all nine cells tested (three type I, six type II cells) (Fig. 6) . These results suggest that presynaptic opioid receptors modulate GABA release from axon terminals arising from spontaneously firing neurons within the preparation and that presynaptic ␦ receptors are located on the terminals of axons arising from quiescent, possibly, type II GP neurons.
DISCUSSION
GP neuronal subtypes
In this study, two major subtypes of GP neuron have been characterized electrophysiologically. These neurons are similar but not identical to those reported previously Llinás, 1994, 1997) . Therefore, they were provisionally classed as type I and type II GP neurons in accordance with these previous studies.
Type I neurons (34% of total recordings) showed no evidence of inward rectification or anodal break depolarizations. These cells exhibited a low input resistance, consistent with type I neurons of Nambu and Llinás (1994) . However, they differed from those reported previously because they were spontaneously active at resting membrane potentials and showed shorter action potential and AHP durations (Nambu and Llinás, 1994) .
Sixty-six percent of cells recorded in the GP showed marked anomalous inward rectification on hyperpolarization (I h ) [this current was readily blocked by 2 mM cesium and 100 M ZD 7288 (our unpublished observations)] and anodal break depolarizations often accompanied by action potential firing. These neurons also had a relatively high input resistance and were either quiescent or firing spontaneous action potentials at a tonic rate. These cells probably correspond to the type II cells described by Nambu and Llinás (1994) , which exhibited rebound depolarizations and a high input resistance.
The discrepancies in neuronal characteristics between the present study and that of Nambu and Llinás (1994) may arise from differences in species (rats vs guinea pigs), slice preparation (300-m-thick slices vs 600 -1000 m strips) or recording technique (whole-cell vs sharp microelectrode).
Presynaptic inhibition of striatopallidal GABA A IPSCs
Met-enkephalin and the opioid receptor agonist DAMGO depressed the GABA A receptor-mediated IPSCs evoked by stimulation within the striatum. Met-enkephalin also induced an increase in paired-pulse facilitation (an effect blocked by the selective opioid receptor antagonist CTOP) and reduced the frequency of mIPSCs. The ␦ opioid receptor agonist DPDPE had no effect on striatal evoked IPSCs. These results indicate that enkephalin, acting at presynaptic but not ␦ opioid receptors, may reduce GABA release from striatopallidal terminals. This is in agreement with binding and immunohistochemical studies, which have demonstrated the presynaptic location of opioid receptors on striatopallidal terminals (Abou Khalil et al., 1984; Olive et al., 1997) and suggests a possible autoinhibitory role for endogenous enkephalin released from striatopallidal terminals.
Presynaptic inhibition of pallidopallidal GABA A IPSCs in the GP
IPSCs evoked by stimulation within the GP were depressed by the activation of both and ␦ opioid receptors. The opioid receptor agonist DAMGO inhibited locally evoked I PSCs and reduced the frequency of mI PSC s, confirming a presynaptic locus of action. This could be caused by an action on striatopallidal terminals or intrinsic GP terminals. An indication of whether these terminals arose from striatal neurons or intrinsic GP cells was given by the study of sI PSC s, which were both TTX-and picrotoxin-sensitive, implying dependence on spontaneously firing GABA-containing neurons whose cell bodies have been preserved in the preparation. Application of either met-enkephalin or DAMGO reduced the frequency of sI PSC s. Because postsynaptic responses to opioid receptor agonists were rarely observed, this reduction in sI PSC s is most likely to be a result of the presynaptic opioid receptor modulation of GABA release. Because the major GABA input to the GP arises from the striatum and the majority of these neurons are quiescent, it is likely that this modulation is on presynaptic terminals of spontaneously firing GP cells. One possible candidate cell type is the type I GP neuron.
DPDPE also reduced IPSCs evoked by local GP stimulation and reduced the frequency of mIPSCs, indicative of a presynaptic location of ␦ receptors in the GP. The modulation of GABA release by ␦ opioid receptors from rat slices of GP has been reported previously (Dewar et al., 1987) , although the precise location of this presynaptic modulation could not be determined. (n ϭ 7) . B, Time course showing the effect of the ␦ opioid receptor agonist DPDPE (1 M) on the normalized I PSC amplitude evoked by stimulation of the striatum in parasagittal slices in the presence of C NQX (10 M) and DL-AP-5 (100 M). DPDPE has no significant effect on the evoked I PSC (n ϭ 5). However, the I PSC evoked in each of these five cells was inhibited by DAMGO (1 M). C, Paired I PSC s recorded from the same cell in response to the same stimulation at an interval of 50 msec in control ( i) and DAMGO (1 M) (ii). iii, The pair of I PSC s recorded in the presence of DAMGO have been scaled so that the conditioning (first) responses with and without drug are of similar amplitude. The ratio of the test (second) response in DAMGO has increased, indicative of a presynaptic site of action. Paired IPSCs recorded in the presence of the opioid receptor antagonist C TOP (1 M) (iv) and C TOP plus DAMGO (1 M) (v), and ratio (vi). In the presence of CTOP, there was no depression of the conditioning I PSC by DAMGO and no change in the paired-pulse ratio. Currents resulting from a 10 mV hyperpolarizing step precede all I PSC pairs.
In contrast, DPDPE had no effect on sIPSCs. Therefore, the presynaptic ␦ receptors may well be located on the presynaptic terminals of quiescent GP neurons (possibly type II) or another nonstriatal source of GABA input to the GP.
Despite the evidence for pallidopallidal GABA terminals expressing functional presynaptic and ␦ opioid receptors, this has yet to be corroborated by anatomical studies. A number of studies have indicated scattered cells in the GP, each expressing high 4 and without drug are of similar amplitude. The increase in ratio of the test (second) response is indicative of a presynaptic site of action of metenkephalin. C, mI PSC s were recorded from chloride loaded cells (E Cl , ϩ1 mV) in the presence of TTX (1 M), C NQX (10 M), and DL-AP-5 (100 M) at a holding potential of Ϫ80 mV. mI PSC s were collected over a period of 120 sec. The same time frame was taken 3 min after drug application. i, Control mI PSC s and those recorded after application of met-enkephalin (30 M). ii, Cumulative frequency and amplitude distributions (derived from 120 sec of data) before and after met-enkephalin. Met-enkephalin reduced the frequency of mI PSC s ( p Ͻ 0.01) but not their amplitude. levels of opioid receptor mRNA or moderate levels of ␦ mRNA (Delfs et al., 1994; Mansour et al., 1994) . mRNA for both and ␦ opioid receptors have also been found in scattered cells in the human GPe (Peckys and Landwehrmeyer, 1999) . Therefore, opioid receptor protein transport from GP somata to presynaptic terminals remains a possibility.
Postsynaptic effects of opioid receptor activation in the GP
Immunohistochemical studies of postsynaptic opioid receptor localization are primarily in agreement with the in situ hybridization data (Bausch et al., 1995; Ding et al., 1996; Olive et al., 1997) . In addition, postsynaptic DOR1 (antibody to ␦ opioid receptors) immunostaining has been reported to be present on pallidostriatal feedback neurons (Olive et al., 1997) . These neurons may be equivalent to the discrete population of GP cells, which selectively innervate subpopulations of interneurons in the striatum (Bevan et al., 1998) .
We did not observe f unctional postsynaptic and ␦ receptors in GP neurons because changes in holding current on metenkephalin application were rare. A small proportion of cells did show changes in mIPSC amplitude on application of DAMGO (one of seven cells) or DPDPE (one of four cells), indicative of postsynaptic receptors. However, we were unable to correlate these changes with a specific neuronal population. It may well be that there is a small population of GP neurons, as yet unidentified, which possess functional postsynaptic opioid receptors. The lack of a measurable functional change per se does not preclude the fact that postsynaptic opioid receptors may be linked to other effector mechanisms other than those that alter membrane conductance or potential. Postsynaptic opioid receptor activation may produce long-term changes in GP cell physiology via alterations in gene expression. Indeed, systemic morphine administration has been shown to increase the expression of transcription factors, such as Fos, in the striatum and nucleus accumbens (Bontempi and Sharp, 1997) .
Implications for opioid modulation of GABA transmission in the GP and relation to movement disorders
This study supports the notion that endogenous enkephalin acts at both presynaptic opioid receptors on striatopallidal terminals and and ␦ presynaptic opioid receptors on pallidopallidal terminals to modulate the release of GABA. Thus, enkephalin appears to regulate inhibitory synaptic activity in the GP and may guard against total repression of GP GABA output. The classical model predicts that dopamine depletion leads to this excessive striatopallidal activity, inhibition of GP neurons, and a reduction in GP GABA output. However, a number of studies have indicated that, in experimental parkinsonism, the GP shows increased excitatory responses and increases in burst firing, which may indeed enhance GABA release from GP neurons (Tremblay et al., 1989; Filion and Tremblay, 1991; Chesselet and Delfs, 1996) . This apparent paradoxical increase in GP neuronal activity may be a direct result of an increase in STN excitatory input (Chesselet and Delfs, 1996) or alternatively caused by the overriding adaptive mechanism of enkephalin reducing GABA release from both striatopallidal terminals and terminals of intrinsic GP axon collaterals. In keeping with this function of enkephalin, levels of mRNA and protein are increased in the striatum of parkinsonism animals (Augood et al., 1989; Asselin et al., 1994) , although a small proportion of pallidal neurons show increased mRNA for enkephalin after 6-hydroxydopamine lesions (Marshall et al., 1999) .
␦ Presynaptic receptors appear to be preferentially located on the terminals of quiescent cells, possibly type II neurons. In contrast, opioid receptors appear to play a role in the modulation of GABA release on pallidopallidal terminals of tonically firing type I or type II GP neurons. The overall physiological function of both these presynaptic opioid receptors will be dependent on the degree of STN excitation, the extent of GP neuronal interconnectivity, and the association between quiescent and tonically firing neurons, which at present is unknown. Figure 6 . Depression of sI PSC s by activation of opioid receptors. A, sIPSCs in a single GP neuron recorded at a holding potential of Ϫ50 mV in the presence of CNQX (10 M) and DL-AP-5 (100 M). Bath application of met-enkephalin (30 M) suppressed the frequency and amplitude of sIPSCs. This effect was replicated by the opioid receptor agonist DAMGO (1 M), whereas the ␦ opioid receptor agonist DPDPE (1 M) was without effect. sIPSC s were blocked by TTX (1 M). B, Cumulative frequency distributions of sI PSC s before and after the addition of met-enkephalin ( p Ͻ 0.05) ( i), DAMGO ( p Ͻ 0.05) (ii), and DPDPE (non significant) (iii). Data were collected over a period of 120 sec. Same cell as A.
